Rodman & Renshaw Initiates Coverage On Unity Biotechnology with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Unity Biotechnology (NASDAQ:UBX) with a Buy rating and set a price target of $8.

August 22, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Unity Biotechnology with a Buy rating and a price target of $8, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $8 by Rodman & Renshaw suggests a positive sentiment towards Unity Biotechnology. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100